Allergan's Forest Units to Pay $38 Million Settlement Linked to Fraud and Marketing, Sales Practices

Allergan announces that indirect subsidiaries Forest Laboratories, LLC and Forest Pharmaceuticals, Inc. have reached a civil resolution with the federal government regarding its investigation into the sales and marketing practices promoting Bystolic, Savella and Namenda during a four-year period beginning January 1, 2008. The issue involved alleged payments to physicians for conducting speaker programs.

Forest has also agreed to settlements with state Medicaid programs in connection with the same inquiry.